Treatment of acute myeloid leukemia patients aged more than 75 years: Results of the E-AML-01 trial of the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG)

Leukemia and Lymphoma

Volumn 47, Issue 10, 2006, Pages 2062-2069

  Mori, Mayumi ^a   Ohta, Masatsugu ^a   Miyata, Akira ^b   Higashihara, Masaaki ^c   Oshimi, Kazuo ^d   Kimura, Hideo ^e   Yagasaki, Fumiharu ^f   Sunami, Kazutaka ^g  

^a Tokyo Metropolitan Institute of Gerontology   (Japan)

^b CHUGOKU CENTRAL HOSPITAL   (Japan)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^f SAITAMA MEDICAL UNIVERSITY   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION OKAYAMA MEDICAL CENTER   (Japan)

Author keywords

Acute myeloid leukemia; Behenoyl cytosine arabinoside; Chemotherapy; Elderly

Indexed keywords

ACLARUBICIN; ALLOPURINOL; CYTARABINE; DAUNORUBICIN; ENOCITABINE; ETOPOSIDE; MERCAPTOPURINE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE HEART FAILURE; AGED; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHROMOSOME 20Q; CHROMOSOME 5Q; CHROMOSOME 7Q; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION 16; CHROMOSOME TRANSLOCATION 8; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; ELDERLY CARE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; INTERSTITIAL PNEUMONIA; JAPAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; STOMATITIS; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 33750445292     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600733317     Document Type: Article

References (32)

1. Brincker, H. (1985) Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission Cancer Treat Rep, 69, pp. 5-11.
2. Groupe Francais de Morphologie Hematologique. (1987) French registry of acute leukemia and myelodysplastic syndromes. Age distribution and hemogram analysis of the 4496 cases recorded during 1982-1983 and classified according to FAB criteria Cancer, 60, pp. 1385-1394.
3. Johnson, P and Liu Yin, J. (1993) Acute myeloid leukaemia in the elderly: Biology and treatment Br J Haematol, 83, pp. 1-6.
4. Taylor, P and Reid, M and Stark, A and Bown, N and Hamilton, P and Proctor, S. (1995) De novo acute myeloid leukaemia in patients over 55-years-old: A population-based study of incidence, treatment and outcome Leukemia, 9, pp. 231-237.
5. Leith, C and Kopecky, K and Godwin, J and McConnell, T and Slovak, M and Chen, I and (1997) Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study Blood, 89, pp. 3323-3329.
6. Smith, S and Le Beau, M and Huo, D and Karrison, T and Sobecks, R and Anastasi, J and (2003) Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series Blood, 102, pp. 43-52.
7. Leone, G and Voso, M and Sica, S and Morosetti, R and Pagano, L. (2001) Therapy related leukemias: Susceptibility, prevention and treatment Leuk Lymphoma, 41, pp. 255-276.
8. Grimwade, D and Walker, H and Harrison, G and Oliver, F and Chatters, S and Harrison, C and (2001) The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial Blood, 98, pp. 1312-1320.
9. Baudard, M and Marie, J and Cadiou, M and Viguié, F and Zittoun, R. (1994) Acute myelogenous leukaemia in the elderly: Retrospective study of 235 consecutive patients Br J Haematol, 86, pp. 82-91.
10. Stone, R and Mayer, R. (1993) The approach to the elderly patient with acute myeloid leukemia Hematol Oncol Clin North Am, 7, pp. 65-79.
11. DeLima, M and Ghaddar, H and Pierce, S and Estey, E. (1996) Treatment of newly diagnosed acute myelogenous leukaemia in patients aged 80 years and above Br J Haematol, 93, pp. 89-95.
12. Ferrara, F and Annunziata, M and Copia, C and Magrin, S and Mele, G and Mirto, S. (1998) Therapeutic options and treatment results for patients over 75 years of age with acute myeloid leukemia Haematologica, 83, pp. 126-131.
13. Vey, N and Coso, D and Bardou, V and Stoppa, A and Braud, A and Bouabdallah, R and (2004) The benefit of induction chemotherapy in patients age ≥ 75 years Cancer, 101, pp. 325-331.
14. Mori, M and Nisimura, H and Urabe, A and Tamura, K and Makino, S and Okabe, K and (2000) A randomized trial of conventional dose versus reduced dose in BHAC-DM therapy for acute myelogenous leukemia in elderly patients Jpn J Clin Hematol, 41, pp. 109-114.
15. Kimura, K and Ohno, R and Amaki, I and Hattori, K and Hirota, Y and Hoshino, A and (1985) Treatment of acute myelogenous leukemia in adults with N4-behenoyl-1-β-D-arabinofuranosylcytosine Cancer, 56, pp. 1913-1917.
16. Ohno, R and Kato, Y and Nagura, E and Murase, T and Okumura, M and Yamada, H and (1986) Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length J Clin Oncol, 4, pp. 1740-1747.
17. Yoshida, M and Suda, K and Tsuboyama, A and Sasaki, R and Kitagawa, S and Kano, Y and (1989) Behenoyl cytosine arabinoside, aclacinomycin A, 6-mercaptopurine, and prednisolone combination therapy for acute non-lymphocytic leukaemia in adults Eur J Haematol, 43, pp. 1-6.
18. Nakamura, T and Ueda, T. (1988) Pharmacokinetics and action mechanism of N4-behenoyl-1-β-D-arabinofuranosylcytosine (BHAC) in leukemia chemotherapy. In Cancer Chemotherapy: Challenges for the Future. (pp. 289-295). Tokyo: Excerpta Medica.
19. Aoshima, M and Tsukagoshi, S and Sakurai, Y and Oh-ishi, J and Ishida, T and Kobayashi, H. (1977) N4-Behenoyl-1-β-D-arabinofuranosylcytosine as a potential new antitumor agent Cancer Res, 37, pp. 2481-2486.
20. Ueda, T and Nakamura, T and Ando, S and Kagawa, D and Sasada, M and Uchino, H and (1983) Pharmacokinetics of N4-behenoyl-1-β-D-arabinofuranosylcytosine in patients with acute leukemia Cancer Res, 43, pp. 3412-3416.
21. Ozawa, S and Sugiyama, Y and Mitsuhashi, J and Inaba, M. (1989) Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells Cancer Res, 49, pp. 3823-3828.
22. Miyawaki, S and Tanimoto, M and Kobayashi, T and Minami, S and Tamura, J and Omoto, E and (1999) No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: The JALSG-AML92 study Int J Hematol, 70, pp. 97-104.
23. Kantarjian, H and O'Brien, S and Cortes, J and Giles, F and Faderl, S and Jabbour, E and (2006) Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome Cancer. [Epub ahead of print]
24. Öberg, G and Killander, A and Björeman, M and Gahrton, G and Grimfors, G and Gruber, A and (2002) Long-term follow-up of patients ≥ 60-year-old with acute myeloid leukaemia treated with intensive chemotherapy Eur J Haematol, 68, pp. 376-381.
25. Rowe, J and Neuberg, D and Friedenberg, W and Bennett, J and Paietta, E and Makary, A and (2004) A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: A trial by the Eastern Cooperative Oncology Group Blood, 103, pp. 479-485.
26. Baer, M and George, S and Dodge, R and O'Loughlin, K and Minderman, H and Caligiuri, M and (2002) Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720 Blood, 100, pp. 1224-1232.
27. Goldstone, A and Burnett, A and Wheatley, K and Smith, A and Hutchinson, R and Clark, R. (2001) Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: The results of the United Kingdom Medical Research Council AML11 trial Blood, 98, pp. 1302-1311.
28. Wahlin, A and Markevärn, B and Golovleva, I and Nilsson, M. (2001) Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia Br J Haematol, 115, pp. 25-33.
29. Löfgren, C and Paul, C and Åström, M and Hast, R and Hedenius, M and Lerner, R and (2004) Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: A Swedish multicentre randomized trial Br J Haematol, 124, pp. 474-480.
30. Gupta, V and Chun, K and Yi, Q and Minden, M and Schuh, A and Wells, R and (2005) Disease biology rather than age is the most important determinant of survival of patients ≥ 60 years with acute myeloid leukemia treated with uniform intensive therapy Cancer, 103, pp. 2082-2090.
31. Anderson, J and Kopecky, K and Willman, C and Head, D and O'Donnell, M and Luthardt, F and (2002) Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: A Southwest Oncology Group study Blood, 100, pp. 3869-3876.
32. Reiffers, J and Raynal, F and Broustet, A. (1980) Acute myeloblastic leukemia in elderly patients: Treatment and prognostic factors Cancer, 45, pp. 2816-2820.